《“奥密克戎时代COVID-19对免疫功能低下人群的影响：基于人群的观察性INFORM研究的见解”的勘误》[《柳叶刀区域健康 - 欧洲》35卷（2023年）100747]
Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747].
作者信息
Evans Rachael A, Dube Sabada, Lu Yi, Yates Mark, Arnetorp Sofie, Barnes Eleanor, Bell Samira, Carty Lucy, Evans Kathryn, Graham Sophie, Justo Nahila, Moss Paul, Venkatesan Sudhir, Yokota Renata, Ferreira Catia, McNulty Richard, Taylor Sylvia, Quint Jennifer K
机构信息
Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom.
AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom.
出版信息
Lancet Reg Health Eur. 2024 Jul 25;44:101008. doi: 10.1016/j.lanepe.2024.101008. eCollection 2024 Sep.
Abstract
[This corrects the article DOI: 10.1016/j.lanepe.2023.100747.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.lanepe.2023.100747。]
相似文献
1
Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747].《“奥密克戎时代COVID-19对免疫功能低下人群的影响：基于人群的观察性INFORM研究的见解”的勘误》[《柳叶刀区域健康 - 欧洲》35卷（2023年）100747]
Lancet Reg Health Eur. 2024 Jul 25;44:101008. doi: 10.1016/j.lanepe.2024.101008. eCollection 2024 Sep.
2
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].《意大利肿瘤药物监测登记处与临床试验中患者基线特征的比较：一项真实世界横断面研究》的勘误 [《柳叶刀区域健康 - 欧洲》41 (2024) 100912]
Lancet Reg Health Eur. 2024 May 21;42:100940. doi: 10.1016/j.lanepe.2024.100940. eCollection 2024 Jul.
3
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].《意大利肿瘤药物监测登记与临床试验中患者基线特征的比较：一项真实世界横断面研究》勘误 [《柳叶刀区域健康 - 欧洲》41 (2024) 100912]
Lancet Reg Health Eur. 2024 Jun 24;42:100973. doi: 10.1016/j.lanepe.2024.100973. eCollection 2024 Jul.
4
Corrigendum to "Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI)" [The Lancet Regional Health - Europe 40 (2024) 100892].《欧洲先天性感染倡议组织（ECCI）关于先天性巨细胞病毒感染的产前、新生儿期及产后管理的共识推荐》勘误 [《柳叶刀区域健康——欧洲》40（2024）100892]
Lancet Reg Health Eur. 2024 Jun 24;42:100974. doi: 10.1016/j.lanepe.2024.100974. eCollection 2024 Jul.
5
Corrigendum to "Risk of cancer in young and older patients with congenital heart disease and the excess risk of cancer by syndromes, organ transplantation and cardiac surgery: Swedish health registry study (1930-2017)" [The Lancet Regional Health-Europe 18 (2022) 100407].《先天性心脏病年轻和老年患者的癌症风险以及综合征、器官移植和心脏手术导致的额外癌症风险：瑞典健康登记研究（1930 - 2017年）》勘误 [《柳叶刀区域健康 - 欧洲》18 (2022) 100407]
Lancet Reg Health Eur. 2024 Apr 16;40:100911. doi: 10.1016/j.lanepe.2024.100911. eCollection 2024 May.
6
Corrections to "Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study" [The Lancet Regional Health - Europe 6 (2021) 100142].对《莱姆病螺旋体病治疗后持续症状的患病率：一项前瞻性观察队列研究》[《柳叶刀区域健康 - 欧洲》6（2021）100142]的更正
Lancet Reg Health Eur. 2023 Mar 15;27:100622. doi: 10.1016/j.lanepe.2023.100622. eCollection 2023 Apr.
7
Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829].对《保护婴儿免受呼吸道合胞病毒疾病侵害：长效单克隆抗体与母体疫苗接种的影响及成本效益比较》的勘误 [《柳叶刀区域健康——欧洲》38 (2024) 100829]
Lancet Reg Health Eur. 2024 Sep 11;45:101073. doi: 10.1016/j.lanepe.2024.101073. eCollection 2024 Oct.
8
Withdrawal notice to: <Describing the unvaccinated as the main driver of the current COVID-19 situation in Germany should not be based on analyzing pre-pandemic patterns of contacts> <[The Lancet Regional Health Europe 12 (2022) 100290]>.撤回通知对象：<将未接种疫苗者描述为德国当前新冠疫情主要驱动因素的说法不应基于对疫情前接触模式的分析><[《柳叶刀-欧洲区域健康》12 (2022) 100290]>
Lancet Reg Health Eur. 2022 Jan;12:100298. doi: 10.1016/j.lanepe.2021.100298. Epub 2022 Jan 10.
9
Corrigendum to "Lower risk of multi-system Inflammatory Syndrome in Children (MIS-C) with the Omicron variant" [The Lancet Regional Health - Western Pacific 27 (2022) 100604].《儿童多系统炎症综合征（MIS-C）与奥密克戎变异株相关的较低风险》勘误 [《柳叶刀西太平洋地区健康》27卷（2022年）100604]
Lancet Reg Health West Pac. 2023 Jun;35:100808. doi: 10.1016/j.lanwpc.2023.100808. Epub 2023 May 30.
10
Correction to "Concerns about the external validity of the study 'prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'-authors' reply".对《莱姆病治疗后持续症状的患病率：一项前瞻性观察队列研究》的关注——作者回复的勘误
Lancet Reg Health Eur. 2022 Jul 22;19:100449. doi: 10.1016/j.lanepe.2022.100449. eCollection 2022 Aug.
引用本文的文献
1
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients.远缘冠状病毒的交叉中和作用与来自免疫功能正常和免疫功能低下的接种过疫苗的SARS-CoV-2感染患者的刺突S2特异性抗体相关。
Res Sq. 2024 Dec 5:rs.3.rs-5487774. doi: 10.21203/rs.3.rs-5487774/v1.
Zotero 插件